These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26803592)

  • 1. Glycated haemoglobin does not accurately predict average capillary glucose in non insulin-treated type 2 diabetes: The PRISMA study experience.
    Trevisan R; Bonizzoni E; Bosi E; Ceriello A; Cucinotta D; Giorgino F; Tiengo A; Scavini M
    Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):169-70. PubMed ID: 26803592
    [No Abstract]   [Full Text] [Related]  

  • 2. ADAG study group data links A1C levels with empirically measured blood glucose values - new treatment guidelines will now be needed.
    Klonoff DC
    J Diabetes Sci Technol; 2014 May; 8(3):439-43. PubMed ID: 24876603
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments to "The astonishing hypothesis" by Niels de Fine Olivarius (NdFO).
    Lauritzen T; Borch-Johnsen K
    Prim Care Diabetes; 2013 Apr; 7(1):69. PubMed ID: 23122746
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study.
    Abitbol A; Jain AB; Tsoukas MA; Sigalas J; Galm BP; Lee J; Qureshy KS; Collins C; Woo VC
    Diab Vasc Dis Res; 2024; 21(3):14791641241253967. PubMed ID: 38733368
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control.
    Bloomgarden Z
    J Diabetes; 2017 Aug; 9(8):722-723. PubMed ID: 28513098
    [No Abstract]   [Full Text] [Related]  

  • 6. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
    Mannucci E; Monami M; Ceriello A; Rotella CM
    Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
    [No Abstract]   [Full Text] [Related]  

  • 7. A Simplified Approach Using Rate of Change Arrows to Adjust Insulin With Real-Time Continuous Glucose Monitoring.
    Klonoff DC; Kerr D
    J Diabetes Sci Technol; 2017 Nov; 11(6):1063-1069. PubMed ID: 28884599
    [No Abstract]   [Full Text] [Related]  

  • 8. Home glucose monitoring makes little difference in type 2 diabetes.
    J Fam Pract; 2005 Nov; 54(11):936. PubMed ID: 16299946
    [No Abstract]   [Full Text] [Related]  

  • 9. Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials.
    Schnell O; Hanefeld M; Monnier L
    J Diabetes Sci Technol; 2014 May; 8(3):609-14. PubMed ID: 24876626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
    Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
    Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time spent in target range assessed by self-monitoring blood glucose associates with glycated hemoglobin in insulin treated patients with diabetes.
    Cutruzzolà A; Irace C; Parise M; Fiorentino R; Pio Tripodi PF; Ungaro S; Babinsky V; Gnasso A
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1800-1805. PubMed ID: 32669240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
    Wareham NJ; Pfister R
    Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients.
    Ajjan RA; Abougila K; Bellary S; Collier A; Franke B; Jude EB; Rayman G; Robinson A; Singh BM
    Diab Vasc Dis Res; 2016 May; 13(3):211-9. PubMed ID: 27000105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is glycemic control a quinidine-like intervention?
    Bloomgarden ZT
    J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
    Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
    Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
    Borghi C; Ventura F
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy.
    Yamagishi SI
    Diabetes Metab Res Rev; 2018 Oct; 34(7):e3024. PubMed ID: 29763999
    [No Abstract]   [Full Text] [Related]  

  • 18. Should the target A1C level be less than 7 percent? Yes: This should be the target for most patients.
    Peterson K
    Am Fam Physician; 2012 Dec; 86(12):1-2. PubMed ID: 23316992
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
    Matthews DR; Zinman B; Tong C; Meininger G; Polidori D
    Diabet Med; 2016 Dec; 33(12):1744-1747. PubMed ID: 26600115
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance of glycemic control.
    Shahady EJ
    J Fam Pract; 2011 Sep; 60(9 Suppl):S4-6. PubMed ID: 21912776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.